Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2025)

Historic Common Equity for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $129.2 million.

  • Artiva Biotherapeutics' Common Equity fell 3570.82% to $129.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.2 million, marking a year-over-year decrease of 3570.82%. This contributed to the annual value of $186.6 million for FY2024, which is 21519.98% up from last year.
  • Per Artiva Biotherapeutics' latest filing, its Common Equity stood at $129.2 million for Q3 2025, which was down 3570.82% from $149.0 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Common Equity high stood at $201.0 million for Q3 2024, and its period low was -$191.1 million during Q2 2024.
  • Moreover, its 3-year median value for Common Equity was -$11.1 million (2023), whereas its average is -$880900.0.
  • Per our database at Business Quant, Artiva Biotherapeutics' Common Equity surged by 23271.09% in 2024 and then crashed by 3570.82% in 2025.
  • Artiva Biotherapeutics' Common Equity (Quarter) stood at -$162.0 million in 2023, then soared by 215.2% to $186.6 million in 2024, then crashed by 30.76% to $129.2 million in 2025.
  • Its Common Equity stands at $129.2 million for Q3 2025, versus $149.0 million for Q2 2025 and $168.8 million for Q1 2025.